These results suggest that DPP-4 inhibitors reduce the risk of major adverse cardiovascular events compared to diabetes drugs (with the exception of SGLT2 inhibitors which can also be used to treat chronic heart failure) and placebo [26,27,28]. The gene discussed is DPP4; the disease is congestive heart failure.